美英就药品定价达成原则性协议

Core Points - The US and UK have reached a principled agreement on drug pricing, with the UK agreeing to pay 25% more for new drugs by 2035, which is expected to increase NHS annual spending by approximately £3 billion [1] - The agreement is seen as a significant step for the UK pharmaceutical industry, ensuring £6.6 billion worth of drug exports to the US will continue to enjoy zero tariffs for the next three years [4] - The agreement will also adjust the voluntary scheme for branded drug pricing, reducing the rebate percentage from 23.5%-35.6% to 15%, making UK drugs more competitive [4] Financial Implications - NHS's annual spending on innovative therapies is projected to rise from £14.4 billion to £30 billion, increasing its GDP share from 0.3% to 0.6% [1] - The increase in the cost-effectiveness threshold for quality-adjusted life years (QALY) from £20,000-£30,000 to £25,000-£35,000 is expected to allow 3-5 additional drugs to be approved each year [5] Industry Reactions - The UK government views the agreement as a means to boost domestic pharmaceutical development, countering previous investment delays from companies like Merck and AstraZeneca [4] - The UK Pharmaceutical Industry Association (ABPI) has welcomed the agreement, believing it will restore industry confidence and create a more stable investment environment [4] - Concerns have been raised by the Liberal Democrats regarding the financial burden on the NHS, suggesting that the agreement may lead to increased pressure on other critical healthcare resources [2][3]